Abukhodair Abdulkarim W, Abukhudair Walid, Alqarni Mohammed S
Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Jeddah, SAU.
Cardiac Surgery, King Fahd Armed Forces Hospital, Jeddah, SAU.
Cureus. 2021 Dec 17;13(12):e20485. doi: 10.7759/cureus.20485. eCollection 2021 Dec.
Hypertension (HTN) is a chronic disease that affects more than 972 million people throughout the world, which is usually associated with endothelial dysfunction. Scientists are closely investigating endothelial dysfunction and have recently discovered the endothelium-derived relaxing factor (EDRF) known as NO (nitric oxide), which is derived from a semi-essential amino acid, L-arginine, by the action of endothelial nitric oxide synthase (eNOS). Production of adequate amounts of NO by vascular endothelial cells is essential to maintain normal blood pressure and prevent the development of HTN. Asymmetrical dimethylarginine (ADMA) is an endogenous NOS inhibitor that is increased in those with HTN especially in patients with renal dysfunction. In the present review, the role of L-arginine, arginine transporters, and ADMA in the pathobiology of HTN and their potential clinical significance are discussed.
高血压（HTN）是一种影响全球超过9.72亿人的慢性疾病，通常与内皮功能障碍有关。科学家们正在密切研究内皮功能障碍，最近发现了被称为一氧化氮（NO）的内皮源性舒张因子，它是由半必需氨基酸L-精氨酸在内皮型一氧化氮合酶（eNOS）的作用下产生的。血管内皮细胞产生足够量的NO对于维持正常血压和预防高血压的发生至关重要。不对称二甲基精氨酸（ADMA）是一种内源性一氧化氮合酶抑制剂，在高血压患者尤其是肾功能不全患者中含量增加。在本综述中，讨论了L-精氨酸、精氨酸转运体和ADMA在高血压病理生物学中的作用及其潜在的临床意义。
